ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
덴바시아(Dengvaxia) 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 4억 470만 달러로 성장할 전망이며, CAGR 17%에 이를 것으로 보입니다. 예측 기간 동안 성장의 배경에는 뎅기열 발생률 상승, 정부 자금 증가, 민관 협력, 뎅기열 예방에 대한 일반 시민의 의식 제고, 헬스케어 인프라 강화 등이 있습니다. 예측 기간 주요 동향으로는 백신 기술의 진보, 지속적인 연구 개발, 백신 전달 방법의 혁신, 새로운 제제의 개발, 백신의 보관 및 유통 기술의 향상 등을 들 수 있습니다.
뎅기열의 이환율 증가는 덴바시아(Dengvaxia) 시장의 성장을 견인할 것으로 예측됩니다. 뎅기열은 예묘에 의해 매개되는 바이러스 감염병으로 인플루엔자와 같은 증상 및 강한 통증을 일으키며, 중증화되면 뎅기출혈열 및 뎅기쇼크증후군 등의 합병증을 일으켜 생명을 위협할 수도 있습니다. 뎅기열 유행의 증가는 기후변화, 도시화, 여행 증가, 모기 번식지 확대 등의 요인에 의한 것으로 감염률 상승과 예방 및 치료에 대한 수요 증대로 이어지고 있습니다. 덴바시아(Dengvaxia)는 바이러스에 대한 방어 반응을 생산하도록 면역계를 자극함으로써 뎅기열을 예방하고, 감염이나 위중한 합병증의 위험을 감소시키며, 유행 지역에서의 공중보건 결과를 개선하는 효과적인 백신입니다. 예를 들어 2024년 6월 미국 질병예방관리센터(CDC)는 2024년 남북 아메리카의 뎅기열 환자 수가 970만 명을 넘었으며, 2023년 460만 명에서 두 배로 늘었다고 보고했습니다. 푸에르토리코에서는 1,498명의 환자가 발생해 공중보건 비상사태가 선포됐고, 미국인 여행자에게서는 745명의 환자가 보고됐습니다. 그 결과 뎅기열의 높은 발생률이 덴바시아(Dengvaxia) 시장의 성장을 뒷받침하고 있습니다.
해외여행 증가가 덴바시아(Dengvaxia) 시장의 성장을 가속할 것으로 예측됩니다. 관광, 비즈니스, 교육 등을 포함한 해외 여행에서는 뎅기열 등의 감염병이 만연할 위험이 높아집니다. 이 위험의 고조가 백신 등의 예방 대책에 대한 수요를 뒷받침하고 있습니다. 덴바시아(Dengvaxia)는 유행 지역에서의 뎅기열 감염으로부터 여행자를 보호하고 월경 질병 전파의 위험을 줄여줍니다. 예를 들어 2024년 5월 국가통계국은 영국 해외 방문자 수가 크게 증가해 2022년 3,120만 명에서 2023년 3,800만 명으로 증가했다고 보고했습니다. 그 결과, 해외 여행의 증가는 덴바시아(Dengvaxia) 시장의 확대에 공헌할 것으로 생각됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 바이오의약품 시장에서의 제품 특성
분자 유형
투여 경로(ROA)
작용기전(MOA)
안전성 및 유효성
제4장 시장 동향 및 전략
제5장 시장 : 금리, 인플레이션, 지정학적 요인, 신형 코로나와 그 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제6장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 덴바시아(Dengvaxia): PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 덴바시아(Dengvaxia) 시장 : 성장률 분석
세계의 덴바시아(Dengvaxia) 시장 실적 : 규모 및 성장(2019-2024년)
세계의 덴바시아(Dengvaxia) 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 덴바시아(Dengvaxia): 전체 시장 규모(TAM)
제7장 세계의 가격 분석 및 예측
제8장 시장 세분화
세계의 덴바시아(Dengvaxia) 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
덴바시아(Dengvaxia)
기타
세계의 덴바시아(Dengvaxia) 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
클리닉
공중위생 프로그램
세계의 덴바시아(Dengvaxia) 시장 : 질환별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
과거에 감염된 사람의 예방
고위험 지역에서의 보호
여행자 예방접종
소아와 청소년의 사용
제9장 세계의 임상적응증 역학
약제의 부작용
임상적응증의 발병률 및 유병률
제10장 지역별 및 국가별 분석
세계의 덴바시아(Dengvaxia) 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 덴바시아(Dengvaxia) 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 경쟁 구도와 기업 프로파일
덴바시아(Dengvaxia) 시장 : 경쟁 구도
덴바시아(Dengvaxia) 시장 : 기업 프로파일
Sanofi Pasteur Inc
제29장 세계 시장 : 파이프라인 분석
제30장 세계 시장 경쟁 벤치마킹 및 대시보드
제31장 주요 인수합병(M&A)
제32장 최근 시장 동향
제33장 시장의 잠재력이 높은 국가, 부문 및 전략
덴바시아(Dengvaxia) 시장(2029년) : 새로운 기회를 제공하는 국가
덴바시아(Dengvaxia) 시장(2029년) : 새로운 기회를 제공하는 부문
덴바시아(Dengvaxia) 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제34장 부록
AJY
영문 목차
영문목차
Dengvaxia is a recombinant vaccine designed to protect against dengue fever, a viral disease transmitted by Aedes mosquitoes. It works by stimulating the immune system to generate a targeted response, preventing infection and reducing the risk of severe complications. This vaccine plays a key role in public health efforts in areas where dengue is endemic.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main category of dengvaxia includes the vaccine itself and other related options. Dengvaxia is the first vaccine specifically developed to prevent dengue fever. It aims to provide immunity against the virus that causes the disease, helping to lessen the severity and frequency of dengue outbreaks. As an essential tool in regions prone to dengue, it has been used in various countries to protect at-risk populations. Dengvaxia is distributed through hospitals, clinics, and public health programs, and is administered for multiple purposes, such as preventing the disease in individuals with prior exposure, offering protection in high-risk areas, immunizing travelers, and supporting pediatric and adolescent vaccination.
The dengvaxia market research report is one of a series of new reports from The Business Research Company that provides dengvaxia market statistics, including dengvaxia industry global market size, regional shares, competitors with a dengvaxia market share, detailed dengvaxia market segments, market trends and opportunities, and any further data you may need to thrive in the dengvaxia industry. This dengvaxia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The dengvaxia market size is expected to see rapid growth in the next few years. It will grow to $404.7 million in 2029 at a compound annual growth rate (CAGR) of 17%. The growth in the forecast period can be attributed to rising incidence of dengue outbreaks, increased government funding, collaboration between public and private sectors, growing public awareness of dengue prevention, and enhanced healthcare infrastructure. Major trends in the forecast period include advancements in vaccine technology, ongoing research and development, innovations in vaccine delivery methods, development of new formulations, and better vaccine storage and distribution techniques.
The increasing incidence of dengue is expected to drive the growth of the dengvaxia market. Dengue is a viral infection transmitted by Aedes mosquitoes, causing flu-like symptoms, intense pain, and, in severe cases, complications such as dengue hemorrhagic fever or dengue shock syndrome, which can be life-threatening. The rising prevalence of dengue is attributed to factors such as climate change, urbanization, increased travel, and the expansion of mosquito breeding grounds, leading to higher infection rates and an increased demand for prevention and treatment. Dengvaxia is an effective vaccine that prevents dengue by stimulating the immune system to produce protective responses against the virus, reducing the risk of infection and severe complications, and improving public health outcomes in endemic areas. For example, in June 2024, the Centers for Disease Control and Prevention (CDC) reported that the Americas had over 9.7 million dengue cases in 2024, double the 4.6 million cases in 2023. Puerto Rico declared a public health emergency with 1,498 cases, and 745 cases were reported among U.S. travelers. As a result, the high incidence of dengue is propelling the growth of the dengvaxia market.
The rise in international travel is expected to fuel the growth of the dengvaxia market. International travel, which includes tourism, business, and education, increases the risk of spreading infectious diseases such as dengue. This heightened risk drives the demand for preventive measures such as vaccines. Dengvaxia helps protect travelers from contracting dengue in endemic areas and reduces the risk of disease transmission across borders. For instance, in May 2024, the Office for National Statistics reported a significant increase in the number of international visits to the UK, rising from 31.2 million in 2022 to 38.0 million in 2023. As a result, the growth in international travel will contribute to the expansion of the dengvaxia market.
The rising healthcare expenditures are expected to further accelerate the growth of the dengvaxia market. Healthcare expenditures refer to the financial resources allocated by governments, private entities, or individuals for healthcare services, medical treatments, and health-related activities. The growth in healthcare expenditures is driven by factors such as the increasing demand for medical services, advancements in healthcare technology, and the rising prevalence of chronic diseases, leading to greater investment in healthcare infrastructure and treatments. The expenditure on Dengvaxia focuses on prevention, aiming to reduce the long-term costs of treating dengue and managing outbreaks. For example, in May 2024, the Office for National Statistics reported a 5.6% increase in nominal healthcare expenditure from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth in 2022. Therefore, rising healthcare expenditures will further stimulate the growth of the dengvaxia market.
The key company operating in the dengvaxia market is Sanofi Pasteur Inc.
Asia-Pacific was the largest region in the dengvaxia market in 2024. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in dengvaxia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the dengvaxia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dengvaxia market consists of sales of dengvaxia (CYD-TDV), disposable syringes and needles, pre-filled syringes of dengvaxia, and unit-dose packaging. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Dengvaxia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on dengvaxia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for dengvaxia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dengvaxia market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Dengvaxia; Other Types
2) By Distribution Channel: Hospitals; Clinics; Public Health Programs
3) By Clinical Indication: Prevention In Previously Infected Individuals; Protection In High-Risk Regions; Traveler Immunization; Pediatric And Adolescent Use
Companies Mentioned: Sanofi Pasteur Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Dengvaxia Market Characteristics
3. Dengvaxia Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Dengvaxia Market Trends And Strategies
5. Dengvaxia Market -Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
6. Global Dengvaxia Growth Analysis And Strategic Analysis Framework
6.1. Global Dengvaxia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Dengvaxia Market Growth Rate Analysis
6.4. Global Dengvaxia Historic Market Size and Growth, 2019 - 2024, Value ($ Million)
6.5. Global Dengvaxia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)
6.6. Global Dengvaxia Total Addressable Market (TAM)
7. Global Dengvaxia Pricing Analysis & Forecasts
8. Dengvaxia Market Segmentation
8.1. Global Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
Dengvaxia
Other Types
8.2. Global Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
Hospitals
Clinics
Public Health Programs
8.3. Global Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
Prevention In Previously Infected Individuals
Protection In High-Risk Regions
Traveler Immunization
Pediatric And Adolescent Use
9. Global Dengvaxia Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Dengvaxia Market Regional And Country Analysis
10.1. Global Dengvaxia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
10.2. Global Dengvaxia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11. Asia-Pacific Dengvaxia Market
11.1. Asia-Pacific Dengvaxia Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.3. Asia-Pacific Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.4. Asia-Pacific Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
12. China Dengvaxia Market
12.1. China Dengvaxia Market Overview
12.2. China Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.3. China Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.4. China Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
13. India Dengvaxia Market
13.1. India Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.2. India Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.3. India Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14. Japan Dengvaxia Market
14.1. Japan Dengvaxia Market Overview
14.2. Japan Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.3. Japan Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.4. Japan Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15. Australia Dengvaxia Market
15.1. Australia Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.2. Australia Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.3. Australia Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16. South Korea Dengvaxia Market
16.1. South Korea Dengvaxia Market Overview
16.2. South Korea Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.3. South Korea Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.4. South Korea Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17. Western Europe Dengvaxia Market
17.1. Western Europe Dengvaxia Market Overview
17.2. Western Europe Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.3. Western Europe Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.4. Western Europe Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18. UK Dengvaxia Market
18.1. UK Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.2. UK Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.3. UK Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19. Germany Dengvaxia Market
19.1. Germany Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.2. Germany Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.3. Germany Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20. France Dengvaxia Market
20.1. France Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.2. France Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.3. France Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21. Eastern Europe Dengvaxia Market
21.1. Eastern Europe Dengvaxia Market Overview
21.2. Eastern Europe Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.3. Eastern Europe Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.4. Eastern Europe Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22. North America Dengvaxia Market
22.1. North America Dengvaxia Market Overview
22.2. North America Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.3. North America Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.4. North America Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23. USA Dengvaxia Market
23.1. USA Dengvaxia Market Overview
23.2. USA Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.3. USA Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.4. USA Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24. Canada Dengvaxia Market
24.1. Canada Dengvaxia Market Overview
24.2. Canada Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.3. Canada Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.4. Canada Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25. South America Dengvaxia Market
25.1. South America Dengvaxia Market Overview
25.2. South America Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.3. South America Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.4. South America Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26. Middle East Dengvaxia Market
26.1. Middle East Dengvaxia Market Overview
26.2. Middle East Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.3. Middle East Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.4. Middle East Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27. Africa Dengvaxia Market
27.1. Africa Dengvaxia Market Overview
27.2. Africa Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.3. Africa Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.4. Africa Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
28. Dengvaxia Market Competitive Landscape And Company Profiles
28.1. Dengvaxia Market Competitive Landscape
28.2. Dengvaxia Market Company Profiles
28.2.1. Sanofi Pasteur Inc Overview, Products and Services, Strategy and Financial Analysis
29. Global Dengvaxia Market Pipeline Analysis
29.1. High Level Clinic Trail Information
30. Global Dengvaxia Market Competitive Benchmarking And Dashboard
31. Key Mergers And Acquisitions In The Dengvaxia Market
32. Recent Developments In The Dengvaxia Market
33. Dengvaxia Market High Potential Countries, Segments and Strategies
33.1 Dengvaxia Market In 2029 - Countries Offering Most New Opportunities
33.2 Dengvaxia Market In 2029 - Segments Offering Most New Opportunities
